{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:35:27Z","timestamp":1791279327124,"version":"4.1.0"},"reference-count":112,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1136\/gutjnl-2016-313425","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T02:12:56Z","timestamp":1487902376000},"page":"966-974","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":146,"title":["Dietary and pharmacological treatment of abdominal pain in IBS"],"prefix":"10.1136","volume":"66","author":[{"given":"Michael","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boeckxstaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"key-10.1136\/gutjnl-2016-313425-1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrgastro.2014.103","article-title":"Neuroplasticity and dysfunction after gastrointestinal inflammation","volume":"11","author":"Brierley","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrgastro.2013.29","article-title":"Extrinsic primary afferent signalling in the gut","volume":"10","author":"Brookes","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-3","doi-asserted-by":"crossref","DOI":"10.1097\/01.mcg.0000156114.22598.1b","article-title":"Visceral hypersensitivity","volume":"39","author":"Delgado-Aros","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrgastro.2015.121","article-title":"Towards a systems view of IBS","volume":"12","author":"Mayer","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-5","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-6","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMcp0801447","article-title":"Irritable bowel syndrome","volume":"358","author":"Mayer","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.1136\/gutjnl-2016-313425-7","first-page":"40","article-title":"Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology","volume":"109","author":"Mertz","year":"1995"},{"key":"key-10.1136\/gutjnl-2016-313425-8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1053\/gast.2002.33601","article-title":"Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds","volume":"122","author":"Bouin","year":"2002","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2982.2000.00231.x","article-title":"Comparison of cortical potentials evoked by mechanical and electrical stimulation of the rectum","volume":"12","author":"Hobday","year":"2000","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2982.2002.00332.x","article-title":"Compliance, tone and sensitivity of the rectum indifferent subtypes of irritable bowel syndrome","volume":"14","author":"Steens","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2982.2004.00511.x","article-title":"Intolerance to visceral distension in functional dyspepsia or irritable bowel syndrome: an organ specific defect or a pan intestinal dysregulation?","volume":"16","author":"Bouin","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2982.2004.00508.x","article-title":"Abnormalrectal motor physiology in patients with irritable bowelsyndrome","volume":"16","author":"Kwan","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cgh.2008.02.060","article-title":"Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome","volume":"6","author":"Camilleri","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2007.07.024","article-title":"Altered rectal perception in irritable bowel syndrome is associated with symptom severity","volume":"133","author":"Posserud","year":"2007","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2010.07.053","article-title":"Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome","volume":"140","author":"Tillisch","year":"2011","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gut.2006.117390","article-title":"Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity","volume":"56","author":"Dorn","year":"2007","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ajg.2013.105","article-title":"Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life","volume":"108","author":"Bohn","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ajg.2013.24","article-title":"Food and symptom generation in functional gastrointestinal disorders: physiological aspects","volume":"108","author":"Farr\u00e9","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF01072052","article-title":"A deficiency of dietary fiber may be one cause of certain colonic and venous disorders","volume":"21","author":"Burkitt","year":"1976","journal-title":"Am J Dig Dis"},{"key":"key-10.1136\/gutjnl-2016-313425-20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2015.16994","article-title":"Constipation: advances in diagnosis and treatment","volume":"315","author":"Wald","year":"2016","journal-title":"JAMA"},{"key":"key-10.1136\/gutjnl-2016-313425-21","doi-asserted-by":"crossref","first-page":"a2313","DOI":"10.1136\/bmj.a2313","article-title":"Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis","volume":"337","author":"Ford","year":"2008","journal-title":"BMJ"},{"key":"key-10.1136\/gutjnl-2016-313425-22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2036.2011.04602.x","article-title":"Systematic review: the effects of fibre in the management of chronic idiopathic constipation","volume":"33","author":"Suares","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-23","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2015.02.005","article-title":"Food components and irritable bowel syndrome","volume":"148","author":"Gibson","year":"2015","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00394-015-0922-1","article-title":"Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis","volume":"55","author":"Marsh","year":"2016","journal-title":"Eur J Nutr"},{"key":"key-10.1136\/gutjnl-2016-313425-25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000448280","article-title":"Fecal fermentation in irritable bowel syndrome: influence of dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols","volume":"94","author":"Valeur","year":"2016","journal-title":"Digestion"},{"key":"key-10.1136\/gutjnl-2016-313425-26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/gutjnl-2014-307264","article-title":"Diets that differ in their FODMAP content alter the colonic luminal microenvironment","volume":"64","author":"Halmos","year":"2015","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-27","article-title":"Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome","author":"Hustoft","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1017\/S0029665116000021","article-title":"Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet","volume":"75","author":"Staudacher","year":"2016","journal-title":"Proc Nutr Soc"},{"key":"key-10.1136\/gutjnl-2016-313425-29","article-title":"FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial","author":"McIntosh","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-30","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/j.gastro.2015.07.054","article-title":"Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial","volume":"149","author":"B\u00f6hn","year":"2015","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2016.434","article-title":"A randomized controlled trial comparing the low FODMAP diet vs. modified NICE Guidelines in US adults with IBS-D","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-32","article-title":"British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults","author":"McKenzie","year":"2016","journal-title":"J Hum Nutr"},{"key":"key-10.1136\/gutjnl-2016-313425-33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.13706","article-title":"Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome","volume":"44","author":"Peters","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.gastrohep.2015.07.009","article-title":"The low-FODMAP diet for irritable bowel syndrome: Lights and shadows","volume":"39","author":"Molina-Infante","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-35","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3748\/wjg.v22.i7.2219","article-title":"Gut microbiota role in irritable bowel syndrome: New therapeutic strategies","volume":"22","author":"Distrutti","year":"2016","journal-title":"World J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/cns.12490","article-title":"Stress and the microbiota-gut-brain axis in visceral pain: relevance to irritable bowel syndrome","volume":"22","author":"Moloney","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-37","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2006.00734.x","article-title":"Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome","volume":"101","author":"Whorwell","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-38","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1365-2036.2003.01543.x","article-title":"A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome","volume":"17","author":"Kim","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2982.2005.00695.x","article-title":"A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating","volume":"17","author":"Kim","year":"2005","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/ajg.2014.202","article-title":"Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-41","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.3748\/wjg.v21.i10.3072","article-title":"Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis","volume":"21","author":"Didari","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1365-2982.2008.01156.x","article-title":"A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome\u2013a randomized controlled trial with primary care physicians","volume":"20","author":"Enck","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-2008-1027702","article-title":"Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo","volume":"47","author":"Enck","year":"2009","journal-title":"Z Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/2050640615602571","article-title":"Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation","volume":"4","author":"Spiller","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"key-10.1136\/gutjnl-2016-313425-45","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/MCG.0000000000000528","article-title":"A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome: a multicenter, randomized, double-blind, placebo-controlled, crossover trial","volume":"51","author":"Giannetti","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jpeds.2016.04.003","article-title":"Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial","volume":"174","author":"Weizman","year":"2016","journal-title":"J Pediatr"},{"key":"key-10.1136\/gutjnl-2016-313425-47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.1136\/gutjnl-2016-313425-48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-49","doi-asserted-by":"crossref","first-page":"S658","DOI":"10.1016\/S0016-5085(15)32224-1","article-title":"Durability of benefit in IBS-D patients responding to a 2-week course of rifaximin: results from TARGET 3","volume":"148","author":"Pimentel","year":"2015","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-50","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0016-5085(15)30242-0","article-title":"Effects of rifaximin on urgency, bloating, and abdominal pain in patients with IBS-D: a randomized, controlled, repeat treatment study","volume":"148","author":"Chey","year":"2015","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-51","first-page":"S653","article-title":"Characterizing the effect of rifaximin on individual symptoms of IBS-D: findings from the open-label phase of TARGET 3","volume":"148","author":"Chang","year":"2015","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.13437","article-title":"Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea","volume":"43","author":"Pimentel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gut.2005.075127","article-title":"Use and abuse of hydrogen breath tests","volume":"55","author":"Simr\u00e9n","year":"2006","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-54","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/gut.2009.205476","article-title":"Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS","volume":"60","author":"Yu","year":"2011","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-55","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/ctg.2016.32","article-title":"Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome","volume":"7","author":"Acosta","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2982.2009.01442.x","article-title":"Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort","volume":"22","author":"Manabe","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/gut.42.6.845","article-title":"Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome","volume":"42","author":"Fukudo","year":"1998","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01318114","article-title":"Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide","volume":"31","author":"Narducci","year":"1986","journal-title":"Dig Dis Sci"},{"key":"key-10.1136\/gutjnl-2016-313425-59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2006.02938.x","article-title":"Systematic review: the efficacy of treatments for irritable bowel syndrome\u2013a European perspective","volume":"24","author":"Tack","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-60","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003460.pub2","article-title":"Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome","author":"Quartero","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/gutjnl-2016-313425-61","first-page":"60","article-title":"Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy","volume":"23","author":"Baldi","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-62","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1365-2036.1998.00397.x","article-title":"Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study","volume":"12","author":"Battaglia","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-63","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00042737-200212000-00008","article-title":"Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome","volume":"14","author":"Glende","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-64","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2036.2011.04730.x","article-title":"Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome","volume":"34","author":"Clav\u00e9","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2036.1988.tb00677.x","article-title":"The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations","volume":"2","author":"Hawthorn","year":"1988","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0304-3940(01)02527-7","article-title":"Menthol: a natural analgesic compound","volume":"322","author":"Galeotti","year":"2002","journal-title":"Neurosci Lett"},{"key":"key-10.1136\/gutjnl-2016-313425-67","first-page":"539","article-title":"The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases","volume":"3","author":"Juergens","year":"1998","journal-title":"Eur J Med Res"},{"key":"key-10.1136\/gutjnl-2016-313425-68","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/nmo.12334","article-title":"Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders","volume":"26","author":"Walstab","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-69","first-page":"2169","article-title":"TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain","volume":"154","author":"Liu","year":"2013"},{"key":"key-10.1136\/gutjnl-2016-313425-70","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCG.0b013e3182a88357","article-title":"Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"48","author":"Khanna","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-71","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10620-015-3858-7","article-title":"A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms","volume":"61","author":"Cash","year":"2016","journal-title":"Dig Dis Sci"},{"key":"key-10.1136\/gutjnl-2016-313425-72","first-page":"367","article-title":"Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis","volume":"58","author":"Ford","year":"2009","journal-title":"Meta-analysis. Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-73","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ajg.2014.148","article-title":"Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-74","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-75","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/14656566.2015.1002770","article-title":"Expert Opinion: American College of Gastroenterology monograph on the management of irritable bowel syndrome","volume":"16","author":"Camilleri","year":"2015","journal-title":"Exp Opin Pharmacother"},{"key":"key-10.1136\/gutjnl-2016-313425-76","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","article-title":"Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum","volume":"135","author":"Yadav","year":"2008","journal-title":"Cell"},{"key":"key-10.1136\/gutjnl-2016-313425-77","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4088\/JCP.14m09580","article-title":"Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study","volume":"77","author":"Lee","year":"2016","journal-title":"J Clin Psychiatr"},{"key":"key-10.1136\/gutjnl-2016-313425-78","article-title":"Exposure to psychotropics in the French older population living with dementia: a nationwide population-based study","author":"Breining","journal-title":"Int J Geriatr Psychiatr"},{"key":"key-10.1136\/gutjnl-2016-313425-79","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/nmo.12617","article-title":"Serotonin and colonic motility","volume":"27","author":"Kendig","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-80","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","article-title":"The serotonin signaling system: from basic understanding to drug development for functional GI disorders","volume":"132","author":"Gershon","year":"2007","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-81","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-82","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","article-title":"Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Andresen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-83","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s10620-016-4162-x","article-title":"Ischemic colitis as a complication of medication use: an analysis of the Federal Adverse Event Reporting System","volume":"61","author":"Bielefeldt","year":"2016","journal-title":"Dig Dis Sci"},{"key":"key-10.1136\/gutjnl-2016-313425-84","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/11590690-000000000-00000","article-title":"The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies","volume":"34","author":"Lewis","year":"2011","journal-title":"Drug Saf"},{"key":"key-10.1136\/gutjnl-2016-313425-85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1572-0241.2004.04097.x","article-title":"Occurrence of colon ischemia in relation to irritable bowel syndrome","volume":"99","author":"Cole","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-86","first-page":"1617","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. See comment in PubMed Commons below Gut","volume":"63","author":"Garsed","year":"2014"},{"key":"key-10.1136\/gutjnl-2016-313425-87","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cgh.2013.11.024","article-title":"Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea","volume":"12","author":"Fukudo","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-88","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.gastro.2015.10.047","article-title":"Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women","volume":"150","author":"Fukudo","year":"2016","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-89","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-90","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mayocp.2016.01.015","article-title":"Lubiprostone is effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"91","author":"Li","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"key-10.1136\/gutjnl-2016-313425-91","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston","year":"2010","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-92","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2013.09.022","article-title":"Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation","volume":"12","author":"Rao","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-93","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2013.08.017","article-title":"Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3\u2032,5'-monophosphate","volume":"145","author":"Castro","year":"2013","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-94","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.cgh.2013.04.032","article-title":"Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis","volume":"11","author":"Videlock","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.1136\/gutjnl-2016-313425-95","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/ajg.2011.78","article-title":"Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria","volume":"106","author":"Hellstr\u00f6m","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-96","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1612578","article-title":"Ending the opioid epidemic - a call to action","author":"Murthy","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.1136\/gutjnl-2016-313425-97","article-title":"Opioid analgesic use among patients presenting with acute abdominal pain and factors associated with surgical diagnoses","author":"Khemani","journal-title":"Neurogastroenterol and Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-98","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-99","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.1136\/gutjnl-2016-313425-100","article-title":"Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea","author":"Cash","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/gutjnl-2016-313425-101","unstructured":"FDA Adverse Event Reporting System Detailed Report from 2 Jan 2016 to 18 Oct 2016 under Freedom of Information Act. Eluxadoline\/Viberzi. Issued 21 October 2016."},{"key":"key-10.1136\/gutjnl-2016-313425-102","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/gutjnl-2015-309151","article-title":"The role of mast cells in functional GI disorders","volume":"65","author":"Wouters","year":"2016","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-103","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.gastro.2015.12.034","article-title":"Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome","volume":"150","author":"Wouters","year":"2016","journal-title":"Gastroenterology"},{"key":"key-10.1136\/gutjnl-2016-313425-104","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/nmo.12616","article-title":"Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome","volume":"27","author":"Corsetti","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"key-10.1136\/gutjnl-2016-313425-105","article-title":"The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS","author":"Tack","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-106","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2036.2005.02685.x","article-title":"Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome","volume":"22","author":"Lee","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.1136\/gutjnl-2016-313425-107","doi-asserted-by":"crossref","first-page":"G377","DOI":"10.1152\/ajpgi.00085.2011","article-title":"Effect of the \u03b12\u03b4 ligand, pregabalin, on colonic sensory and motor functions in healthy adults","volume":"301","author":"Iturrino","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"key-10.1136\/gutjnl-2016-313425-108","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/gut.2006.110858","article-title":"Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome","volume":"56","author":"Houghton","year":"2007","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.dld.2013.09.002","article-title":"Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome","volume":"46","author":"Iturrino","year":"2014","journal-title":"Dig Liver Dis"},{"key":"key-10.1136\/gutjnl-2016-313425-110","article-title":"Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges and unanswered questions","author":"Camilleri","journal-title":"Am J Physiol (in press)"},{"key":"key-10.1136\/gutjnl-2016-313425-111","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gut.2010.213108","article-title":"The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome","volume":"59","author":"Klooker","year":"2010","journal-title":"Gut"},{"key":"key-10.1136\/gutjnl-2016-313425-112","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.pain.2011.01.027","article-title":"A novel role for TRPM8 in visceral afferent function","volume":"152","author":"Harrington","year":"2011","journal-title":"Pain"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2016-313425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:00:39Z","timestamp":1601053239000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2016-313425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":112,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,4,7]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1136\/gutjnl-2016-313425"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2016-313425","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]}}}